Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation

Lone Schejbel; Marie Fredslund Breinholt; Anne Ortved Gang; Torsten Holm Nielsen; Lars Møller Pedersen; Estrid Høgdall; Peter Nørgaard

doi:10.1002/jha2.489

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation

Lone Schejbel, Marie Fredslund Breinholt, Anne Ortved Gang, Torsten Holm Nielsen, Lars Møller Pedersen, Estrid Høgdall, Peter Nørgaard

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

13 Downloads (Pure)

Abstract

Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.

Originalsprog	Engelsk
Tidsskrift	eJHaem
Vol/bind	3
Udgave nummer	3
Sider (fra-til)	936-939
Antal sider	4
ISSN	2688-6146
DOI	https://doi.org/10.1002/jha2.489
Status	Udgivet - 2022

Bibliografisk note

Adgang til dokumentet

10.1002/jha2.489Licens: CC BY

FulltextForlagets udgivne version, 144 KBLicens: CC BY

Citationsformater

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort : Strong correlation with BCL2 translocation. / Schejbel, Lone; Breinholt, Marie Fredslund; Gang, Anne Ortved; Nielsen, Torsten Holm; Pedersen, Lars Møller ; Høgdall, Estrid; Nørgaard, Peter.

I: eJHaem, Bind 3, Nr. 3, 2022, s. 936-939.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{12f95d40bb1947dca7e59e755bf76cc9,

title = "Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation",

abstract = "Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment na{\"i}ve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.",

author = "Lone Schejbel and Breinholt, {Marie Fredslund} and Gang, {Anne Ortved} and Nielsen, {Torsten Holm} and Pedersen, {Lars M{\o}ller} and Estrid H{\o}gdall and Peter N{\o}rgaard",

note = "{\textcopyright} 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

doi = "10.1002/jha2.489",

language = "English",

volume = "3",

pages = "936--939",

journal = "eJHaem",

issn = "2688-6146",

publisher = "Wiley",

number = "3",

}

TY - JOUR

T1 - Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort

T2 - Strong correlation with BCL2 translocation

AU - Schejbel, Lone

AU - Breinholt, Marie Fredslund

AU - Gang, Anne Ortved

AU - Nielsen, Torsten Holm

AU - Pedersen, Lars Møller

AU - Høgdall, Estrid

AU - Nørgaard, Peter

PY - 2022

Y1 - 2022

N2 - Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.

AB - Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.

U2 - 10.1002/jha2.489

DO - 10.1002/jha2.489

M3 - Journal article

C2 - 36051027

VL - 3

SP - 936

EP - 939

JO - eJHaem

JF - eJHaem

SN - 2688-6146

IS - 3

ER -